HealthcareServices

Global Congenital Adrenal Hyperplasia Market Set for Strong Expansion, Reaching $0.69 Billion With 6.8% CAGR by 2030

February 23, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the congenital adrenal hyperplasia market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Congenital Adrenal Hyperplasia Market size between 2026 and 2035?

The congenital adrenal hyperplasia market has shown strong expansion in recent years. It is forecast to grow from $0.5 billion in 2025 to $0.53 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.1%. The historical increase can be attributed to limited options for enzyme replacement, the requirement for lifelong glucocorticoid therapy, low levels of awareness in developing regions, delayed diagnosis resulting from a lack of screening, and a dependence on hospital-based endocrinology care.

The congenital adrenal hyperplasia market is projected to experience substantial expansion, reaching $0.7 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. This anticipated growth stems from progress in precision medicine, wider availability of genetic testing, increased spending on healthcare, the rise of specialty clinics, and better patient compliance with new drug formulations. Key trends anticipated for this period involve broadened newborn screening initiatives, the development of long-acting and modified-release steroid treatments, enhanced mineralocorticoid and androgen suppression strategies, a growing embrace of multidisciplinary care approaches, and an intensified focus on managing the condition throughout a patient’s life.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21157&type=smp

Which Drivers Are Impacting Market Performance In The Congenital Adrenal Hyperplasia Market?

The increasing need for gene therapy is projected to drive expansion within the congenital adrenal hyperplasia market in the future. Gene therapy is a medical technique involving the modification or manipulation of an individual’s genes to treat or prevent disease. The growing interest in gene therapy stems from progress in genetic research and biotechnology, allowing for more accurate and specific treatments for various conditions, including genetic disorders, cancers, and other long-term ailments. Congenital adrenal hyperplasia (CAH), a condition resulting from gene mutations affecting adrenal hormone production, is a significant area of focus for gene therapy, providing avenues for precise genetic interventions to rectify the root genetic issues and re-establish proper hormone activity. For example, data from April 2024 by the American Society of Gene and Cell Therapy (ASGCT), a professional membership organization based in the US, indicated that among the 1,023 gene therapies being developed for rare diseases, eight of the top 10 rare diseases were oncological. During the second quarter of 2024, 76 gene therapy trials commenced, marking a 25% rise compared to the preceding quarter. Consequently, the increased demand for gene therapy is fueling expansion in the congenital adrenal hyperplasia market.

What Segment Types Are Examined In The Congenital Adrenal Hyperplasia Market?

The congenital adrenal hyperplasia market covered in this report is segmented –

1) By Type: Classic Congenital Adrenal Hyperplasia, Non-Classic Congenital Adrenal Hyperplasia

2) By Treatment And Diagnosis: Diagnosis, Treatment

3) By End-Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes

Subsegments:

1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia, Simple Virilizing Classic Congenital Adrenal Hyperplasia

2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia, Mild Non-Classic Congenital Adrenal Hyperplasia

Which Trends Are Influencing The Development Of The Congenital Adrenal Hyperplasia Market?

Major companies in the congenital adrenal hyperplasia market are increasingly focused on developing innovative treatments, such as CRF1 receptor antagonists, to help regulate cortisol production and diminish adrenal androgen excess. A CRF1 receptor antagonist refers to a drug that specifically blocks the corticotropin-releasing factor 1 (CRF1) receptor to modulate the body’s stress response and reduce excessive adrenal androgen production in conditions like congenital adrenal hyperplasia. For instance, in December 2024, Neurocrine Biosciences, Inc., a US-based biopharmaceutical company, obtained FDA approval for crenessity (crinecerfont), marking the first new treatment for congenital adrenal hyperplasia (CAH) in 70 years. This oral medication operates as a selective antagonist of corticotropin-releasing factor type 1 receptors, thereby assisting in the control of excess adrenocorticotropic hormone (ACTH) and adrenal androgens, while also allowing for reduced glucocorticoid doses. This approval was granted based on data derived from the CAHtalyst Phase 3 studies, which evidenced significant efficacy in lowering androgen levels. Crenessity is projected to be available soon, representing a notable progression in CAH management.

Who Are The Core Companies Influencing Trends In The Congenital Adrenal Hyperplasia Market?

Major companies operating in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., Crinetics Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/congenital-adrenal-hyperplasia-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Congenital Adrenal Hyperplasia Market?

North America was the largest region in the congenital adrenal hyperplasia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Congenital Adrenal Hyperplasia Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21157&type=smp

Browse Through More Reports Similar to the Global Congenital Adrenal Hyperplasia Market 2026, By The Business Research Company

Pituitary Dwarf Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

Congenital Heart Disease Chd Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Pheochromocytoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795